Key Points
Paul te Boekhorst, ICCC CEO, filed Form 3 for 25,329 non-qualified stock options.
Options valued at $149,441 with $5.90 strike price.
Form 3 establishes baseline for tracking future insider transactions.
Filing demonstrates professional governance and executive equity alignment.
Insider trading filings reveal what company leaders really think about their stock. When executives file paperwork with the SEC, it signals confidence or caution. Today we examine a significant insider filing for ICCC ImmuCell Corporation. Paul Francis Olivier te Boekhorst, the company’s President and CEO, filed an initial ownership disclosure in November 2025. The filing covers 25,329 non-qualified stock options valued at approximately $149,441. This Form 3 filing provides transparency into executive compensation and equity holdings at the biotech firm.
Understanding the ICCC Insider Filing
ImmuCell Corporation’s insider filing reveals important details about executive compensation. Paul te Boekhorst holds the dual role of President and CEO at the company. The SEC filing was submitted on November 7, 2025, documenting his equity position.
What Is a Form 3 Filing?
A Form 3 is an initial ownership statement filed by company insiders. This form discloses all securities owned by directors, officers, and major shareholders. It establishes a baseline record for tracking future transactions. The form must be filed within 10 days of an insider taking their position. Form 3 filings are public documents available through the SEC’s EDGAR database.
Non-Qualified Stock Options Explained
Non-qualified stock options (NSOs) are a common executive compensation tool. These options give the holder the right to purchase company shares at a set price. Unlike incentive stock options, NSOs receive different tax treatment. The strike price for te Boekhorst’s options is $5.90 per share. With 25,329 options, the total value at grant was approximately $149,441.
ImmuCell Corporation Stock Position Details
The insider filing provides specific data about te Boekhorst’s equity stake. ImmuCell Corporation currently has a market cap of $76.7 million. The company operates in the biotech and immunology sector. Meyka AI rates ICCC a grade of B based on sector performance and financial metrics.
Option Grant Valuation
The 25,329 non-qualified stock options represent significant executive compensation. At $5.90 per share, the total value reaches $149,441.10. This valuation reflects the strike price at the time of grant. The transaction date listed is September 16, 2028, indicating a future vesting schedule. Options typically vest over multiple years, incentivizing long-term performance.
CEO Compensation Structure
Stock options form a key part of executive pay packages in biotech. They align management interests with shareholder returns. Te Boekhorst’s option grant demonstrates the company’s commitment to retaining leadership. The grant size reflects his critical role as President and CEO. Such equity compensation is standard practice across the healthcare sector.
What This Insider Filing Means for ICCC Investors
Insider filings provide valuable signals about company leadership confidence. Form 3 filings establish the foundation for tracking executive trading activity. This initial disclosure allows investors to monitor future transactions. Te Boekhorst’s substantial option grant shows the board values his leadership. The filing transparency supports investor confidence in corporate governance.
Tracking Future Insider Activity
Once a Form 3 is filed, all subsequent transactions must be reported. Form 4 filings document when insiders buy, sell, or exercise options. These reports are filed within two business days of the transaction. Investors can use this data to identify insider sentiment about stock value. Regular monitoring of insider filings helps build a complete picture of executive confidence.
Biotech Sector Insider Trends
Insider equity compensation is particularly common in biotech companies. Stock options help retain specialized talent in competitive markets. ImmuCell Corporation’s approach aligns with industry standards. The company’s B grade from Meyka AI reflects solid fundamentals. Insider filings like this one demonstrate professional governance practices.
How to Monitor ICCC Insider Trading Activity
Investors can access all insider filings through the SEC’s EDGAR database. These public records provide real-time transparency into executive transactions. Monitoring insider activity helps identify potential investment signals. Form 3, Form 4, and Form 5 filings tell the complete story. Regular review of these documents supports informed investment decisions.
Accessing SEC Filings Online
The SEC’s EDGAR system is free and available to all investors. Search by company name or ticker symbol to find filings. Filter results by form type to focus on insider transactions. Each filing includes detailed transaction information and dates. Bookmark the company’s EDGAR page for easy future reference.
Using Insider Data in Your Research
Insider filings complement other research tools and analysis. Compare insider activity across multiple quarters and years. Look for patterns in buying and selling behavior. Large option grants suggest confidence in future performance. Consistent insider purchases often precede positive announcements.
Final Thoughts
Paul te Boekhorst’s Form 3 filing for ImmuCell Corporation reveals a substantial equity stake through non-qualified stock options. The 25,329 options valued at $149,441 represent significant executive compensation aligned with shareholder interests. This initial ownership disclosure establishes the baseline for tracking future insider transactions at ICCC. Investors should monitor subsequent Form 4 filings to identify any changes in te Boekhorst’s position. The filing demonstrates professional governance practices and provides transparency into leadership equity holdings at the biotech company.
FAQs
A Form 3 is an initial ownership statement filed by company insiders within 10 days of taking their position. It discloses all securities owned by directors, officers, and major shareholders, establishing a baseline record for tracking future insider transactions and is publicly available.
Non-qualified stock options grant executives the right to purchase company shares at a set strike price with different tax treatment than incentive stock options. They serve as executive compensation to align management interests with shareholder returns and incentivize long-term performance.
Te Boekhorst’s 25,329 non-qualified stock options have a strike price of $5.90 per share, totaling approximately $149,441.10 in value. The transaction date of September 16, 2028 indicates a future vesting schedule representing significant executive compensation at ImmuCell.
All insider filings are available through the SEC’s EDGAR database at sec.gov. Search by company name or ticker ICCC to find Form 3, Form 4, and Form 5 filings. These public records provide real-time transparency into executive transactions and are free to access.
The Form 3 filing demonstrates governance transparency at ImmuCell Corporation. Te Boekhorst’s substantial option grant reflects board confidence in his leadership as President and CEO, establishing a baseline for monitoring future insider activity and executive confidence in company prospects.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)